SAB Biotherapeutics (SABS) Common Equity (2020 - 2026)
SAB Biotherapeutics (SABS) reported Common Equity of $214.79 million for Q2 2026, compared with $12.02 million a year earlier and down 5.5% from the prior quarter.
SAB Biotherapeutics (SABS) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, SAB Biotherapeutics posted Common Equity of $151.5 million, up 483.3% from FY2024.
- Common Equity has a five-year compound annual growth rate of 31.2% (FY2020 to FY2025).
- By year, Common Equity came in at $25.97 million in FY2024 (-54.7%), $57.3 million in FY2023 (+84.5%), $31.06 million in FY2022 (-19.4%) and $38.55 million in FY2021 (-1.2%).
- Five-year quarterly Common Equity spans a low of $12.02 million in Q2 2025 and a high of $227.25 million in Q1 2026.
- Year over year, Common Equity gained in four of the last seven quarters, with growth averaging 249.4%.
- The high point for year-over-year Common Equity in five years was Q1 2026 (growth of 961.5%); the low point was Q2 2025 (a decline of 73.9%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $227.25 million (Q1 2026), $151.5 million (Q4 2025) and $165.07 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | SAB Biotherapeutics | 268.01 Mn | 268.01 Mn | - | 214.79 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 214.79 Mn |
| Mar 31, 2026 | 227.25 Mn |
| Dec 31, 2025 | 151.50 Mn |
| Sep 30, 2025 | 165.07 Mn |
| Jun 30, 2025 | 12.02 Mn |
| Mar 31, 2025 | 21.41 Mn |
| Dec 31, 2024 | 25.97 Mn |
| Sep 30, 2024 | 36.90 Mn |
| Jun 30, 2024 | 46.12 Mn |
| Mar 31, 2024 | 52.82 Mn |
| Dec 31, 2023 | 57.30 Mn |
| Sep 30, 2023 | 15.26 Mn |
| Jun 30, 2023 | 19.72 Mn |
| Mar 31, 2023 | 24.40 Mn |
| Dec 31, 2022 | 31.06 Mn |
| Sep 30, 2022 | 30.62 Mn |
| Jun 30, 2022 | 37.12 Mn |
| Mar 31, 2022 | 41.26 Mn |
| Dec 31, 2021 | 38.55 Mn |
| Sep 30, 2021 | 35.08 Mn |
SAB Biotherapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=SABS&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "SABS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=SABS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();